NON-LATEX CONDOM LABELING MUST DETAIL EFFICACY RISKS, LIMIT USE
This article was originally published in The Gray Sheet
Executive Summary
NON-LATEX CONDOM LABELING MUST DETAIL EFFICACY RISKS, LIMIT USE to latex-sensitive individuals in order to be marketed. FDA recently sent a letter to several firms developing non-latex, or "plastic," condoms informing them that labeling must indicate that although laboratory tests appear to demonstrate the devices' effectiveness against sexually transmitted diseases and pregnancy, efficacy has not yet been proven through clinical tests. Labeling also must state that the condoms are recommended only for individuals with latex sensitivities, according to industry officials.
You may also be interested in...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.